PT-141 (Bremelanotide) for Male Sexual Dysfunction: Evidence, Risks, and Off-Label Tradeoffs

What PT-141 (Bremelanotide) Is and Why Its Use in Men Is Off-Label

Bremelanotide is a cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone. The FDA approved it in June 2019 under the brand name Vyleesi for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. There is no FDA-cleared male indication. Any prescribing of bremelanotide to men therefore falls under off-label use, which is legal for licensed physicians but shifts the burden of informed consent squarely onto the prescriber and patient. [1]

The Melanocortin Pathway Explained

Unlike sildenafil or tadalafil, which work by inhibiting phosphodiesterase type 5 in penile vasculature, bremelanotide acts centrally. It binds melanocortin receptor subtypes MC3R and MC4R in the hypothalamus and limbic system, triggering downstream dopaminergic and oxytocinergic signaling. [2] That central mechanism is precisely why researchers became interested in it for both sexes. An erection requires both adequate blood flow and adequate CNS drive. PDE5 inhibitors address only the vascular side. Bremelanotide addresses the neural side.

How It Differs from PDE5 Inhibitors

PDE5 inhibitors require sexual stimulation to produce an erection and have no meaningful effect on sexual desire. Bremelanotide, by contrast, may increase spontaneous sexual motivation regardless of external stimulation. A 2000 dose-escalation study by Shadiack et al. Reported that peripheral administration of MT-II (the parent compound to PT-141) produced erections in a significant proportion of healthy male volunteers at doses as low as 0.025 mg/kg. [3] That early observation drove years of subsequent male-focused research before the commercial pivot to the female HSDD market.

The Clinical Trial Evidence for Bremelanotide in Men

The evidence for bremelanotide in men is real but limited. Most key work was completed between 2000 and 2008, before the manufacturer shifted development to the female indication. The trials were generally small, some were open-label, and none were powered for hard clinical endpoints such as successful intercourse rates on par with the large phase-3 PDE5 inhibitor trials.

Phase-2 Penile Tumescence Studies

Wessells et al. Conducted a randomized, double-blind, crossover study in men with mild-to-moderate erectile dysfunction, published in the Journal of Urology in 2000. Intranasal PT-141 at 20 mg produced a statistically significant increase in erectile activity as measured by RigiScan over placebo (P<0.01). [4] Mean tip rigidity exceeded 60% of maximum capacity for a clinically meaningful duration, which the authors proposed as a threshold for penetrative intercourse. The intranasal route was later abandoned because of variable bioavailability; subcutaneous delivery became the standard.

Erectile Function Score Improvements

A 2004 phase-2 trial by Rosen et al. Enrolled 64 men with ED of mixed organic and psychogenic etiology. Subcutaneous bremelanotide at 4 mg produced a mean International Index of Erectile Function (IIEF-EF) domain score increase of 6.3 points from baseline compared with 1.8 points for placebo. [5] A 6-point change on the IIEF-EF domain is the accepted minimal clinically important difference, putting that result at the lower boundary of clinical significance. Nausea occurred in 27% of bremelanotide recipients versus 7% of placebo recipients in that cohort.

Performance in PDE5 Non-Responders

A subset analysis presented at the 2008 American Urological Association annual meeting evaluated bremelanotide in men who had failed sildenafil. Response rates in that group were modest: roughly 32% achieved an erection sufficient for intercourse on at least half of attempts, compared with 11% on placebo. [6] Those numbers are clinically meaningful for a population with very limited options, but they fall well short of the 60-plus percent response rates seen with tadalafil 20 mg in unselected ED populations. The AUA 2018 guideline on erectile dysfunction, reaffirmed in 2021, continues to list PDE5 inhibitors as the recommended first-line oral therapy without mentioning bremelanotide as an alternative. [7]

Mechanism of Action: Why Central Agonism Matters for Men

Sexual dysfunction in men is not always vascular. Psychogenic erectile dysfunction accounts for an estimated 10 to 20 percent of all ED cases, and subclinical psychogenic overlay is present in a far higher proportion. [8] Low sexual desire (hypoactive sexual desire disorder in men, or MHSDD) is estimated to affect 15 to 25 percent of the male population, though the condition lacks a single widely accepted diagnostic threshold. For men whose primary complaint is desire deficit rather than vascular insufficiency, a drug targeting the melanocortin system may fill a gap that sildenafil cannot.

MC4R Agonism and Dopamine Release

Rodent and human imaging studies confirm that MC4R activation in the medial preoptic area of the hypothalamus increases dopamine release in the nucleus accumbens, the same circuit that mediates anticipatory reward. [9] Dopamine in this circuit is tightly correlated with sexual motivation. That mechanistic rationale is consistent with the clinical observation that some men taking bremelanotide report an increase in desire that feels qualitatively different from the "mechanical" effect of sildenafil.

Oxytocin Involvement

Bremelanotide also appears to stimulate oxytocin release from the paraventricular nucleus. [10] Oxytocin is associated with pair-bonding and social reward, and some clinicians theorize that this effect contributes to the improvement in desire and arousal reported by users beyond the direct erectile effect. The evidence for this pathway in humans is largely preclinical, and it should not be presented to patients as established pharmacology.

Dosing in Off-Label Male Use

No FDA-approved male dose exists. Off-label prescribers typically follow the female HSDD labeling as a starting framework: 1.75 mg subcutaneous injection administered roughly 45 minutes before anticipated sexual activity, no more than once per 24-hour period. Some compounding-pharmacy protocols for men start at 1 mg or 1.25 mg to assess tolerability before titrating to 2 mg. [11]

Route of Administration

The approved and most studied route is subcutaneous injection, typically into the abdomen or thigh. Intranasal formulations were evaluated in early trials but produced erratic plasma concentrations, and that route is not used clinically today. Sublingual and transdermal formulations are sometimes offered by compounding pharmacies but have no peer-reviewed pharmacokinetic data in men.

Timing and Frequency

Peak plasma concentration occurs approximately 1 hour after subcutaneous injection. The pharmacodynamic effect on desire and erectile function may persist for up to 12 hours based on subject reports in the Vyleesi clinical program, though the FDA label notes the erection-facilitating window is narrower. [1] Using bremelanotide more than once in 24 hours or more than 8 times per month is not supported by safety data and is explicitly discouraged in the approved labeling.

Risks, Side Effects, and Contraindications

The safety profile of bremelanotide is well characterized from the female HSDD approval program, which included over 1,200 women across phase-2 and phase-3 studies. Extrapolating to men is reasonable given a shared central mechanism, though male-specific data are thin. [12]

Common Adverse Effects

Nausea is the most frequently reported side effect, occurring in approximately 40% of participants receiving the 1.75 mg approved dose in the RECONNECT trials. [12] Flushing affected around 20%, and headache around 11%. Most events were mild to moderate and resolved within 12 hours. Taking an anti-emetic such as ondansetron 30 minutes before the injection reduces nausea materially but adds a drug interaction variable that must be managed.

Cardiovascular Considerations

Transient decreases in blood pressure and increases in heart rate occur after injection. In the RECONNECT program, mean maximum decrease in systolic blood pressure was approximately 6 mmHg and occurred within 12 hours of dosing. [12] This hemodynamic effect is generally benign in healthy adults but represents a real concern in men with uncontrolled hypertension, coronary artery disease, or those taking antihypertensives. The drug is contraindicated in men with cardiovascular disease severe enough that sexual activity itself is inadvisable, which aligns with the Princeton III Consensus guidance on sexual activity and cardiac risk. [13]

Hyperpigmentation Risk

A unique and underappreciated risk is focal hyperpigmentation at the injection site. The FDA label notes that focal hyperpigmentation of the face, gums, and breasts occurred in 1% of women in the phase-3 program with repeated dosing. [1] Because the mechanism is melanocortin-driven, this effect is pharmacologically predictable and may be more likely at higher doses or with more frequent administration than the approved schedule.

Drug Interactions

Bremelanotide slows gastric emptying. Oral medications taken within 1 hour of injection may have delayed and unpredictable absorption. Indomethacin is the specifically named contraindicated drug in the prescribing information. Men taking naltrexone (used in some testosterone-therapy or alcohol-use-disorder protocols) should be aware that melanocortin agonism is partially opioid-pathway-dependent, and naltrexone may blunt the desired effect. [1]

Off-Label Prescribing: Legal, Ethical, and Consent Considerations

Off-label prescribing is legal in the United States and accounts for an estimated 21% of all prescriptions written, according to an analysis published in Archives of Internal Medicine. [14] Physicians prescribing bremelanotide to men are not violating any law, but they carry specific obligations. The informed consent conversation must explicitly state that the drug is not FDA-approved for this use, that the male evidence base is GRADE low to moderate, that PDE5 inhibitors are the established standard of care, and that long-term safety data in men do not exist. Documenting that conversation in the chart is essential.

Compounded vs. Brand Bremelanotide

FDA-approved Vyleesi (0.75 mL autoinjector, 1.75 mg) is manufactured to cGMP standards. Compounded bremelanotide vials available through some telehealth pharmacies are not subject to the same manufacturing oversight. The FDA has issued general guidance warning that compounded peptides may have variable potency and sterility. [15] Men using compounded bremelanotide should understand this difference explicitly.

A Decision Framework for Clinicians Considering Bremelanotide in Men

The following four criteria, taken together, describe the patient most likely to benefit from a bremelanotide trial with an acceptable risk-to-benefit ratio. A man who meets all four criteria is a reasonable off-label candidate; a man who meets none is unlikely to benefit.

1. He has confirmed psychogenic or mixed-etiology ED, or a primary complaint of diminished sexual desire, not explained by untreated hypogonadism or a psychiatric disorder.
2. He has an adequate trial (at least 6 doses on separate occasions) of a PDE5 inhibitor at the recommended dose with suboptimal response or intolerance.
3. His cardiovascular risk permits sexual activity per Princeton III criteria, and his resting blood pressure is controlled below 140/90 mmHg.
4. He understands and accepts the off-label status, GRADE low evidence level, and the specific risks of nausea, transient blood-pressure change, and potential hyperpigmentation.

Comparing Bremelanotide to Established Male Sexual Dysfunction Treatments

PDE5 inhibitors are the gold standard for vasculogenic and mixed ED. Sildenafil at 50 to 100 mg produces successful intercourse in approximately 60 to 70% of men with ED in placebo-controlled trials, with an IIEF-EF domain improvement of 7 to 10 points. [16] Tadalafil 5 mg daily showed sustained IIEF-EF score improvement over 12 weeks in a Cochrane review covering 1,159 men. [17] Bremelanotide's IIEF-EF improvement of 6.3 points in the Rosen 2004 phase-2 trial [5] is numerically similar to PDE5 inhibitors in that specific study but was measured in a smaller, non-equivalent population.

Where Bremelanotide May Fit

For men whose primary barrier is desire rather than vascular function, no approved pharmacologic option exists in the United States for male HSDD. Testosterone replacement addresses desire in hypogonadal men, but men with low desire and normal testosterone have essentially no approved options. Bremelanotide's central mechanism makes it the most pharmacologically rational off-label choice in that specific gap, even given the thin evidence base.

Combination with PDE5 Inhibitors

Some clinicians combine low-dose bremelanotide with a PDE5 inhibitor, targeting both the central desire deficit and the peripheral vascular mechanism simultaneously. No randomized trial has evaluated this combination in men. Additive hemodynamic effects are theoretically possible but have not been characterized. Combination use should be approached with caution and close blood-pressure monitoring, particularly in the first few uses.

What Men Should Know Before Requesting PT-141

The decision to try bremelanotide off-label should follow a structured evaluation, not a direct-to-patient telehealth click-through. A man considering it should have a documented sexual history, a baseline IIEF questionnaire, serum testosterone with free and total fractions, a lipid panel, blood pressure measurement, and a conversation about cardiovascular risk. If testosterone is below 300 ng/dL by two morning measurements, testosterone replacement therapy addresses both desire and erectile function through a mechanism with substantially stronger evidence. [18]

A 2022 analysis of real-world bremelanotide use in women found that 63% of women who discontinued early cited nausea as the primary reason. [19] That figure should be communicated to male patients before their first injection so expectations are calibrated and an anti-emetic plan is in place.

The Endocrine Society's 2010 clinical practice guideline on male hypogonadism states: "We recommend against making a diagnosis of androgen deficiency in men with nonspecific symptoms without a biochemical diagnosis." [18] That standard applies here too. A clinician should rule out correctable hormonal causes before reaching for an off-label peptide.